Value is all about what a company is worth versus what price it is
available for. If you went into a grocery store and all the bananas were on sale
at half price, they could be considered
In this section, we usually try to help investors determine whether OncBioMune Pharmaceuticals is trading at an attractive price based on the cash flow it is expected to produce in the future. But as OncBioMune Pharmaceuticals has not provided consistent financial data, and the stock also has no analyst forecast or coverage, its intrinsic value cannot be reliably calculated by extrapolating past data or using analyst consensus cash flow predictions.
This is quite a rare situation as 89% of companies covered by Simply Wall St do have a valuation analysis. You can see them here.
Show me the analysis anyway
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
It is not possible to calculate the future cash flow value for
OncBioMune Pharmaceuticals. This is due to cash flow or dividend data being
unavailable. The share price is
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for
it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing
when they are out of season, or how much your home is worth.
The amount the stock market is willing to pay for
is considered below, and whether this is a fair price.
Price based on past earnings
OncBioMune Pharmaceuticals's earnings available for a low price, and how does
this compare to other companies in the same industry?
In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as OncBioMune Pharmaceuticals has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.
This is quite a rare situation as 97% of companies covered by Simply Wall St do have past financial data. You can see them here.
Show me the analysis anyway
The future performance of a company is measured in the same way as past
performance, by looking at estimated
and how much profit it is expected to make.
Future estimates come from
professional analysts. Just like forecasting the weather, they don’t always get
Expected Biotechs industry annual growth in earnings.
Earnings growth vs Low Risk Savings
expected to grow at an
Unable to compare OncBioMune Pharmaceuticals's earnings growth to the low risk savings rate as no estimate data is available.
Growth vs Market Checks
Unable to compare OncBioMune Pharmaceuticals's earnings growth to the United States of America market average as no estimate data is available.
Unable to compare OncBioMune Pharmaceuticals's revenue growth to the United States of America market average as no estimate data is available.
Unable to determine if OncBioMune Pharmaceuticals is high growth as no earnings estimate data is available.
Unable to determine if OncBioMune Pharmaceuticals is high growth as no revenue estimate data is available.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can
be gauged below. We look back 3 years and see if they were any good at
predicting what actually occurred. We also show the highest and lowest estimates
looking forward to see if there is a wide range.
While we do not consider unaudited financials to be a reliable enough to include in our analysis, you can access them on the OTC Markets Website. If you are looking for more of a qualitative research into the company, you can access OncBioMune Pharmaceuticals's filings and announcements here.
OncBioMune Pharmaceuticals's performance over the past 5 years by checking for:
Has earnings increased in past 5 years? (1 check)
Has the earnings growth in the last year exceeded that of the
industry? (1 check)
Is the recent earnings growth over the last year higher than the average annual growth over the
past 5 years? (1 check)
Is the Return on Equity (ROE) higher than 20%? (1 check)
Is the Return on Assets (ROA) above industry average? (1 check)
Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent
earnings report. Some checks require at least 3 or 5 years worth of data.
has a total score of
0/6, see the detailed checks below.
Note: We use GAAP Net Income excluding extraordinary items in all our calculations.
A company's financial position is much like your own financial position,
it includes everything you own
The boxes below represent the relative size of what makes up
OncBioMune Pharmaceuticals's finances.
The net worth of a company is the difference between its assets and liabilities.
OncBioMune Pharmaceuticals's short term (1 year) commitments are greater than its holdings of cash and other short term assets.
OncBioMune Pharmaceuticals's cash and other short term assets cover its long term commitments.
This treemap shows a more detailed breakdown of
OncBioMune Pharmaceuticals's finances. If any of them are yellow this
indicates they may be out of proportion and red means they relate to one of the
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
High level of physical assets or inventory.
OncBioMune Pharmaceuticals has negative shareholder equity (liabilities exceed assets) therefore debt is not covered by short term assets.
Nearly all companies have debt. Debt in itself isn’t
however if the debt is too high, or the company can’t afford to pay the interest
on its debts this may have impacts in the future.
The graphic below shows equity (available funds) and debt, we ideally want to
see the red area (debt) decreasing.
If there is any debt we look at the companies capability to repay it, and
whether the level has increased over the past 5 years.
Management is one of the most important areas of a company. We look at
unreasonable CEO compensation, how long the team and board of directors have
been around for and insider trading.
TENURE AS CEO
Dr. Brian Gill Barnett, MD, is Chief Executive Officer at OncBioMune Pharmaceuticals, Inc. since December 26, 2018. Dr. Barnett was Senior Medical Director of Neratinib, Medical Affairs at Puma Biotechnology since August 2016 and was its Vice President and Head of Medical Affairs. Dr. Barnett served numerous senior level positions at Roche Group subsidiary Genentech from October 2012 to August 2016 provided oversight in the FDA approval and launch of the potential blockbuster breast cancer drug Kadcyla. He served at Genentech as Associate Medical Director of Kadcyla, U.S. Medical Affairs; Medical Director of Kadcyla, U.S. Medical Affairs; and Medical Director, Kadcyla, Global Product Development Oncology. At Genentech, Dr. Barnett served as Director of Medical Oncology. Dr. Barnett served as Head Breast Cancer Research and Treatment Center at Elliott. Dr. Barnett has authored and been integral to many peer-reviewed publications on immunotherapy and delivered oral and poster presentations at leading oncology conferences on regulating cancer with immunotherapy approaches. He is an active member of the American Association of Cancer Research and the American Society of Clinical Oncology. He was a Member of Scientific Advisory Board at OncBioMune Pharmaceuticals, Inc. since October 24, 2016 until December 26, 2018. He completed his medical training as a Fellow, Hematology and Medical Oncology at Tulane University Health Sciences Center. Dr. Barnett earned a Bachelor of Science (BS) degree in Chemistry from Millsaps College, a Doctor of Medicine (MD) degree from the University of Mississippi School of Medicine.
Insufficient data for Brian to compare compensation growth.
Brian's remuneration is lower than average for companies of similar size in United States of America.
Management Team Tenure
Average tenure and age of the
management team in years:
The average tenure for the OncBioMune Pharmaceuticals management team is less than 2 years, this suggests a new team.
Chairman of the Board & Chief Scientific Officer
Chief Executive Officer
CFO & President
Board of Directors Tenure
Average tenure and age of the
board of directors in years:
The tenure for the OncBioMune Pharmaceuticals board of directors is about average.
OncBioMune Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops cancer immunotherapy products. The company has proprietary rights to a breast and prostate patent vaccine, as well as a process for the growth of cancer tumors. Its lead product is ProscaVax that is in the planning stage of a Phase II clinical trial for the treatment of prostate cancer. It also engages in the development and commercialization of specialty drugs. In addition, OncBioMune Pharmaceuticals, Inc. has a portfolio of targeted therapies. OncBioMune Pharmaceuticals, Inc. was founded in 2005 and is based in Baton Rouge, Louisiana.
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.